Tacrine. A cause of fatal hepatotoxicity?

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Journal of Clinical Gastroenterology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00004836-199801000-00015PMID 9492866
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The caffeine breath test does not identify patients susceptible to tacrine hepatotoxicity

  1996cited by this paper
• Alzheimer's disease: how to give and monitor tacrine therapy.

  1995cited by this paper
• Alzheimer's disease: how to give and monitor tacrine therapy.

  1995cited by this paper
• Management of Alzheimer Disease: Today's Options and Tomorrow's Opportunities

  1994cited by this paper
• An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro. Studies with human and rat liver microsomes.

  1993cited by this paper
• A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.

  1992cited by this paper
• Tacrine in Alzheimer's disease

  1992cited by this paper
• A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group.

  1992cited by this paper
• Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine.

  1990cited by this paper
• Acute hepatitis after tetrahydroaminoacridine administration for Alzheimer's disease.

  1990cited by this paper
• HEPATOTOXICITY OF TETRAHYDROACRIDINE

  1988cited by this paper
• Hepatotoxicity of tetrahydroaminoacridine.

  1988cited by this paper
• Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type.

  1986cited by this paper

• Novel tacrine-based multi-target directed Ligands: Enhancing cholinesterase inhibition, NMDA receptor antagonism, and CNS bioavailability for Alzheimer's disease treatment.

  2025cites this paper
• Design and Biological Evaluation of an Al(III)-Alloxazine Complex as a Potential Acetylcholinesterase Inhibitor

  2025cites this paper
• The Tacrine‐Induced Endoplasmic Reticulum Stress in AChE‐Expressed Cells Leads to Improper Assembly and Transport of the Oligomeric Enzyme: Reversal by Trehalose

  2025cites this paper
• Alzheimer’s disease and its treatment–yesterday, today, and tomorrow

  2024cites this paper
• Selenylated Analogs of Tacrine: Synthesis, in Silico and in Vitro Studies of Toxicology and Antioxidant Properties.

  2024cites this paper
• Screening cholinesterase inhibitory potential of selected amines

  2024cites this paper
• Unveiling the impact of Aging on BBB and Alzheimer's disease: Factors and Therapeutic implications.

  2024cites this paper
• Chronic aquatic toxicity assessment of diverse chemicals on Daphnia magna using QSAR and chemical read-across.

  2024cites this paper
• Synthesis, Characterization, Crystal Structure, and cholinesterase Inhibitory Activity of 2-Phenylthiazole Derivatives

  2023cites this paper
• Targets, trials and tribulations in Alzheimer therapeutics.

  2023cites this paper
• Molecular Idiosyncratic Toxicology of Drugs in the Human Liver Compared with Animals: Basic Considerations

  2023cites this paper
• Synthesis and Evaluation of Acetylcholinesterase Inhibitory and Cytotoxic Activities of Pyrano[2,3-d]pyrimidines

  2023cites this paper
• Virtual Screening and Hit Selection of Natural Compounds as Acetylcholinesterase Inhibitors

  2022cites this paper
• Synthesis and Evaluation of Novel S-alkyl Phthalimide- and S-benzyl-oxadiazole-quinoline Hybrids as Inhibitors of Monoamine Oxidase and Acetylcholinesterase

  2022cites this paper
• Asetilkolinesteraz ve Bütirilkolinesteraz Enzimlerinin Alzheimer Hastalığı ile İlişkisi

  2022cites this paper
• Design, Synthesis, and Bioevaluation of Indole Core Containing 2-Arylidine Derivatives of Thiazolopyrimidine as Multitarget Inhibitors of Cholinesterases and Monoamine Oxidase A/B for the Treatment of Alzheimer Disease

  2022cites this paper
• Accuracy and precision of binding free energy prediction for a tacrine related lead inhibitor of acetylcholinesterase with an arsenal of supercomputerized molecular modelling methods: a comparative study

  2021cites this paper
• Pericytes and the Neurovascular Unit: The Critical Nexus of Alzheimer Disease Pathogenesis?

  2021cites this paper
• Synthesis of 1-hydroxy-3-O-substituted xanthone derivatives and their structure-activity relationship on acetylcholinesterase inhibitory effect

  2021cites this paper
• Synthesis, Molecular Docking, and Biological Evaluation of Benzimidazole Derivatives as Selective Butyrylcholinesterase Inhibitors.

  2021cites this paper
• Cholinesterase as a Target for Drug Development in Alzheimer's Disease.

  2020cites this paper
• Efficacy Assessment of an Uncharged Reactivator of NOP-Inhibited Acetylcholinesterase Based on Tetrahydroacridine Pyridine-Aldoxime Hybrid in Mouse Compared to Pralidoxime

  2020cites this paper
• Targeting Enzymes for Pharmaceutical Development: Methods and Protocols

  2020cites this paper
• A Snapshot on the Current Status of Alzheimer's Disease, Treatment Perspectives, In-Vitro and In-Vivo Research Studies and Future Opportunities.

  2019cites this paper
• Tacroximes: novel unique compounds for the recovery of organophosphorus-inhibited acetylcholinesterase.

  2019cites this paper
• Drug-induced liver injury

  2019cites this paper
• Discovery of potent and selective butyrylcholinesterase inhibitors through the use of pharmacophore-based screening.

  2019cites this paper
• Behavioral and biochemical evidences for nootropic activity of boldine in young and aged mice.

  2018cites this paper
• The liver–gut microbiota axis modulates hepatotoxicity of tacrine in the rat

  2018cites this paper
• Design, Synthesis and Biological Evaluation of Novel 2‐Phenylthiazole Derivatives for the Treatment of Alzheimer's Disease

  2017cites this paper
• The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer’s Disease

  2015influential citation
• Synthesis, biological evaluation, and computational studies of Tri- and tetracyclic nitrogen-bridgehead compounds as potent dual-acting AChE inhibitors and hH3 receptor antagonists.

  2014cites this paper
• In‐vitro stability and metabolism of a tacrine–silibinin codrug

  2013cites this paper
• The Current Status of Alzheimer's Disease Treatment

  2012cites this paper
• Chapter 25 – Drug-Induced Liver Injury

  2012cites this paper
• Which psychotropic medications induce hepatotoxicity?

  2012cites this paper
• Synthesis, biological assessment, and molecular modeling of racemic 7-aryl-9,10,11,12-tetrahydro-7H-benzo[7,8]chromeno[2,3-b]quinolin-8-amines as potential drugs for the treatment of Alzheimer's disease.

  2012cites this paper
• Current and Emerging Drug Treatment Options for Alzheimer’s Disease

  2011cites this paper
• Experimental research on nitric oxide and the therapy of Alzheimer disease: a challenging bridge.

  2011cites this paper
• Evidence-Based Liver Chemistry Monitoring in Drug Development

  2009cites this paper
• Investigations into the liver effects of ximelagatran using high content screening of primary human hepatocyte cultures.

  2008cites this paper
• Investigations into the liver effects of ximelagatran using high content screening of primary human hepatocyte cultures

  2008cites this paper
• Targeting acetylcholinesterase to treat neurodegeneration

  2007cites this paper
• Rivastigmine and Parkinson dementia complex

  2007cites this paper
• Tacrine-induced liver damage: an analysis of 19 candidate genes

  2007cites this paper
• Molecular and genetic association of interleukin-6 in tacrine-induced hepatotoxicity

  2007cites this paper
• Study of PMS777, a new type of acetylcholinesterase inhibitor, in human HepG2 cells. Comparison with tacrine and galanthamine on oxidative stress and mitochondrial impairment.

  2006cites this paper
• ‘Hy's law,’ the ‘Rezulin Rule,’ and other predictors of severe drug‐induced hepatotoxicity: putting risk‐benefit into perspective

  2006cites this paper
• Chapter 26 – Drug-Induced Liver Injury

  2006cites this paper
• Chronic Exposure of Rats to Cognition Enhancing Drugs Produces a Neuroplastic Response Identical to that Obtained by Complex Environment Rearing

  2006cites this paper
• Idiosyncratic drug hepatotoxicity

  2005cites this paper
• Therapy of vascular dementia: perspectives and milestones

  2005cites this paper
• A comprehensive listing of bioactivation pathways of organic functional groups.

  2005cites this paper
• [Pharmacological targets in neurodegenerative diseases].

  2003cites this paper
• A Large, Community-Based, Open-Label Trial of Donepezil in the Treatment of Alzheimer’s Disease

  2003cites this paper
• Dianas farmacológicas en las enfermedades neurodegenerativas

  2003cites this paper
• Cholinesterase inhibitors for the treatment of Alzheimer's disease:: getting on and staying on.

  2003cites this paper
• A review of the common properties of drugs with idiosyncratic hepatotoxicity and the "multiple determinant hypothesis" for the manifestation of idiosyncratic drug toxicity.

  2002cites this paper
• 87 CURRENT AND EXPERIMENTAL THERAPEUTICS OF ALZHEIMER DISEASE

  2002cites this paper
• Kinetics of human acetylcholinesterase inhibition by the novel experimental Alzheimer therapeutic agent, tolserine.

  2000cites this paper
• Adverse effects associated with the use of donepezil in general practice in England

  2000cites this paper
• Fulminant Chemical Hepatitis Possibly Associated with Donepezil and Sertraline Therapy

  2000cites this paper
• Plasma tacrine concentrations are significantly increased by concomitant hormone replacement therapy

  1999cites this paper
• Central nervous system stimulants and drugs that suppress appetite

  1998cites this paper